| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $789K | — |
| R&D Expense | $49.1M | -24.1% |
| SG&A Expense | $39.2M | -26.4% |
| Operating Income | -$94.0M | +22.5% |
| Interest Expense | $0 | — |
| Income Tax | $0 | — |
| Net Income | $5.7M | +4088.2% |
| EPS (Basic) | $0.64 | — |
| EPS (Diluted) | $0.64 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $45.8M | +48.6% |
| Accounts Receivable | $157K | — |
| Current Assets | $49.4M | +27.7% |
| Total Assets | $138.2M | -1.2% |
| Current Liabilities | $19.3M | -53.1% |
| Total Liabilities | $94.0M | -25.4% |
| Stockholders' Equity | $44.2M | +220.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.1M | +100.8% |
| Capital Expenditures | $252K | -33.7% |
| Investing Cash Flow | -$42K | -100.0% |
| Financing Cash Flow | $13.9M | +115.4% |
| Free Cash Flow | $865K | +100.6% |